Hua Q, Li Z, Weng Y, Wu Y, Zheng L
Front Med. 2025; .
PMID: 40048137
DOI: 10.1007/s11684-025-1124-8.
Jiang Y, Sun X, Yang C, Song D, Zhou C, Chen X
Front Oncol. 2025; 15:1514281.
PMID: 39990694
PMC: 11842267.
DOI: 10.3389/fonc.2025.1514281.
Feng K, Li J, Li J, Li Z, Li Y
Discov Oncol. 2025; 16(1):225.
PMID: 39985635
PMC: 11846825.
DOI: 10.1007/s12672-025-01870-3.
Jin R, Neufeld L, McGaha T
Nat Cancer. 2025; 6(2):239-252.
PMID: 39962208
DOI: 10.1038/s43018-025-00909-2.
Gorria T, Sierra-Boada M, Rojas M, Figueras C, Marin S, Madurga S
Cancers (Basel). 2025; 17(3).
PMID: 39941865
PMC: 11815897.
DOI: 10.3390/cancers17030498.
Translating CD47-targeted therapy in gastrointestinal cancers: Insights from preclinical to clinical studies.
Chen C, Lu F, Huang H, Pan Y
iScience. 2024; 27(12):111478.
PMID: 39720535
PMC: 11667074.
DOI: 10.1016/j.isci.2024.111478.
A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells.
Zhao X, Ren T, Li S, Wang X, Hou R, Guan Z
Int J Biol Sci. 2024; 20(13):5109-5126.
PMID: 39430253
PMC: 11489172.
DOI: 10.7150/ijbs.99680.
Prognostic Significance and Immune Landscape of an Efferocytosis-Related Gene Signature in Bladder Cancer.
Zheng F, Wang Z, Dong Q, Li S, Xiong S, Yuan Y
Biochem Genet. 2024; .
PMID: 39313721
DOI: 10.1007/s10528-024-10924-0.
An Oxidative Stress Nano-Amplifier for Improved Tumor Elimination and Combined Immunotherapy.
Zhang W, Ran Y, Yang M, Hu Y, Wang Z, Cao Y
Adv Healthc Mater. 2024; 13(31):e2402349.
PMID: 39221686
PMC: 11650535.
DOI: 10.1002/adhm.202402349.
The battle within: cell death by phagocytosis in cancer.
Zhou L, Fan S, Zhang W, Gong Z, Wang D, Tang D
Clin Transl Oncol. 2024; .
PMID: 39167272
DOI: 10.1007/s12094-024-03650-x.
Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Farhangnia P, Khorramdelazad H, Nickho H, Delbandi A
J Hematol Oncol. 2024; 17(1):40.
PMID: 38835055
PMC: 11151541.
DOI: 10.1186/s13045-024-01561-6.
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses.
Wang B, Zhou B, Chen J, Sun X, Yang W, Yang T
J Immunother Cancer. 2024; 12(4).
PMID: 38589249
PMC: 11015199.
DOI: 10.1136/jitc-2023-007808.
Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype.
Sarkar B, Arlauckas S, Cuccarese M, Garris C, Weissleder R, Rodell C
Front Immunol. 2024; 15:1331480.
PMID: 38545103
PMC: 10965546.
DOI: 10.3389/fimmu.2024.1331480.
Targeting the Warburg Effect in Cancer: Where Do We Stand?.
Barba I, Carrillo-Bosch L, Seoane J
Int J Mol Sci. 2024; 25(6).
PMID: 38542116
PMC: 10970388.
DOI: 10.3390/ijms25063142.
Harnessing innate immune pathways for therapeutic advancement in cancer.
Hu A, Sun L, Lin H, Liao Y, Yang H, Mao Y
Signal Transduct Target Ther. 2024; 9(1):68.
PMID: 38523155
PMC: 10961329.
DOI: 10.1038/s41392-024-01765-9.
Biomimetic "Gemini nanoimmunoregulators" orchestrated for boosted photoimmunotherapy by spatiotemporally modulating PD-L1 and tumor-associated macrophages.
Huang H, Li N, Wei X, Li Q, Guo J, Yang G
Acta Pharm Sin B. 2024; 14(3):1345-1361.
PMID: 38486995
PMC: 10935025.
DOI: 10.1016/j.apsb.2023.11.005.
Cholesterol-modified sphingomyelin chimeric lipid bilayer for improved therapeutic delivery.
Wang Z, Li W, Jiang Y, Park J, Gonzalez K, Wu X
Nat Commun. 2024; 15(1):2073.
PMID: 38453918
PMC: 10920917.
DOI: 10.1038/s41467-024-46331-7.
Metabolic rewiring and communication in cancer immunity.
Chapman N, Chi H
Cell Chem Biol. 2024; 31(5):862-883.
PMID: 38428418
PMC: 11177544.
DOI: 10.1016/j.chembiol.2024.02.001.
From monocyte-derived macrophages to resident macrophages-how metabolism leads their way in cancer.
Ammarah U, Pereira-Nunes A, Delfini M, Mazzone M
Mol Oncol. 2024; 18(7):1739-1758.
PMID: 38411356
PMC: 11223613.
DOI: 10.1002/1878-0261.13618.
Targeting lipid metabolism of macrophages: A new strategy for tumor therapy.
Shao N, Qiu H, Liu J, Xiao D, Zhao J, Chen C
J Adv Res. 2024; 68:99-114.
PMID: 38373649
PMC: 11785569.
DOI: 10.1016/j.jare.2024.02.009.